Exact Sciences (EXAS) Corp. will present 10 abstracts demonstrating the breadth of its Precision Oncology portfolio at the 2024 annual San Antonio Breast Cancer Symposium from December 10-13 in ...

EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the early detection ...

Jefferies analyst Tycho Peterson maintained a Buy rating on Exact Sciences (EXAS – Research Report) today and set a price target of $85.00. The company’s shares closed yesterday at $53.92.

In this article, we are going to take a look at where Exact Sciences Corporation (NASDAQ:EXAS) stands against the other genomics stocks. Genomics is the study of genes and how they function.

November 25, 2024--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 10 abstracts demonstrating the breadth of its ...

Exact Sciences reports quarterly GAAP losses of 21 cents per share, which missed the analyst consensus estimate for losses of 20 cents. Quarterly sales of $709 million miss the consensus estimate ...

“Exact Sciences is committed to improving breast cancer care by providing actionable insights that support informed treatment decisions and help achieve the best outcomes for patients across all ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 10 abstracts demonstrating the breadth of its Precision Oncology portfolio at the ...

On the heels of the premiere of its first-ever Spanish-language Cologuard campaign, Exact Sciences is doubling down on its push to raise awareness of colorectal cancer and available screening ...